Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

3.66
1,585,684

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

Talphera, Inc. [ACRX]

Reports for Purchase

Showing records 21 - 40 ( 176 total )

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 21

01/13/2022

Daily Note

Pages: 4

Editorial Outlines DSUVIA''s Potential As a Key Component of Good Opioid Stewardship Practices

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 22

12/16/2021

Daily Note

Pages: 3

New Prospective Study Illustrates Multiple Advantages of DSUVIA Over Conventional Pain Management; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 23

11/16/2021

Company Report

Pages: 9

3Q21 Recap; Lowell Acquisition Expands Pipeline; Moderating PT on Revised DSUVIA U.S. Sales Trajectory

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 24

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ACRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 25

08/17/2021

Company Report

Pages: 8

2Q Recap: Cross-License Deal a Bright Spot, but DSUVIA Sales Need to Ramp Up; Reduce PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 26

07/14/2021

Daily Note

Pages: 3

Agreements Position DZUVEO for Success in Europe and Provides Two NDA-Ready Products to AcelRx; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 27

05/20/2021

Daily Note

Pages: 3

DSUVIA May Provide Analgesic Bridge For Sickle Cell Disease Patients Presenting at the Emergency Department

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 28

05/18/2021

Company Report

Pages: 8

1Q21 Recap; We Begin to See The Light at The End of The COVID-19 Tunnel As DSUVIA Growth Strengthens; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 29

03/25/2021

Daily Note

Pages: 3

Phase 3 Pooled Analysis Provides Yet Further Evidence of Highly Positive Experiences With DSUVIA

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 30

03/16/2021

Company Report

Pages: 8

4Q20 Recap: As Many Covid Restrictions Evaporate by Summer, Expect DSUVIA Ramp Beginning 2H21; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 31

02/18/2021

Company Report

Pages: 8

Expecting DSUVIA Momentum to Continue As Positive Real World Experience Accumulates; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 32

02/17/2021

Daily Note

Pages: 3

FDA Warning Letter on DSUVIA Is a Nothingburger

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 33

12/11/2020

Company Report

Pages: 8

Yet Another Publication Highlights DSUVIA As Superior to IV Opioids for Acute Perioperative Analgesia; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 34

11/19/2020

Daily Note

Pages: 4

DSUVIA''s Multiple Advantages Over IV Fentanyl Highlighted in Peer-Reviewed Journal; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 35

11/06/2020

Company Report

Pages: 8

3Q20 Recap; DSUVIA Procurement Under Milestone C Expected to Begin in 4Q20; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 36

10/09/2020

Daily Note

Pages: 6

DSUVIA''s Clinical and Economic Advantages Elucidated in Two Separate Studies; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 37

09/15/2020

Daily Note

Pages: 3

Formulary Addition Paves the Way to Wider DSUVIA Adoption Across DoD; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 38

08/24/2020

Daily Note

Pages: 3

The Cleveland Clinic to Initiate a Study of DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 39

08/20/2020

Daily Note

Pages: 3

DSUVIA Showed Statistically Significant Advantages Over IV Opioids in Prospective Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Talphera, Inc.

Industry: Medical - Drugs

Record: 40

08/11/2020

Company Report

Pages: 8

2Q20 Recap: We See Near-Term Opportunities as Pillars Supporting Long-Term Objectives; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

// eof